If you could vote on Brexit now which option would you choose?
   

Glaxosmithkline's coronavirus vaccine starts human trials | Business


A coronavirus vaccine being developed in partnership with Glaxosmithkline has begun human clinical trials. The FTSE 100 drugs company is providing its adjuvant technology as part of a collaboration with Clover Biopharmaceuticals, of China. After promising pre-clinical results in animals, the vaccine has begun a phase one study in Perth, Australia. Glaxo and Clover are planning a more in-depth phase two trial, which it is hoped will start later in the year. The partnership with Clover is one of several Covid-19 vaccine projects involving Glaxo, which also include a venture with Sanofi, of France. Glaxo, based in west London, is a leading player in the global vaccines market, along with Sanofi and the American companies Merck and Pfizer.

The Times - June 19, 2020

View the full story here: https://www.thetimes.co.uk/article/glaxosmithklines-coronavirus-vaccine-starts-human-trials-j66mqtwhb